Please login to the form below

Not currently logged in
Email:
Password:

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

Sanofi

French pharmaceutical company Sanofi has invested €170m to expand its existing vaccine production operations in northern France.

The new Val de Reuil facility will allow Sanofi Pasteur to increase supply of its new quadrivalent influenza vaccine VaxigripTetra.

Philippe Luscan, executive vice president, global industrial affairs, Sanofi, said: “Our investment underlines Sanofi’s intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets.”

Sanofi - who has made several investments to improve and expand its vaccine production capabilities - plans to complete the expansion by 2021, and will begin producing vaccines in the new facility in 2022.

David Loew, executive vice president, Sanofi, said: “Influenza continues to be a major public health problem around the world, causing serious complications, hospitalisations and deaths, mostly for certain high-risk individuals.

“As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur’s ability to tackle this underestimated health challenge.”

Article by
Gemma Jones

17th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics